# 2026年1月20日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. GMCL1 控制 53BP1 的稳定性并调节紫杉烷类药物的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41553759)
**期刊：** eLife
**PMID：** 41553759
**DOI：** 10.7554/eLife.106730

### 第一部分 原文与翻译

**英文原标题：** GMCL1 controls 53BP1 stability and modulates taxane sensitivity.

> **英文摘要：**
> Mitotic surveillance pathways monitor the duration of mitosis (M phase) in the cell cycle. Prolonged M phase, caused by spindle attachment defects or microtubule-targeting drugs, triggers formation of the ternary 'mitotic stopwatch pathway' complex (MSP) consisting of 53BP1, USP28, and p53. This complex stabilizes p53, leading to cell cycle arrest or apoptosis in daughter cells. In cancers that are resistant to paclitaxel, a microtubule-targeting agent, cells bypass mitotic surveillance activation, allowing unchecked proliferation, although the underlying mechanisms remain poorly understood. Here, we identify GMCL1 as a key negative regulator of MSP signaling. We show that 53BP1 physically interacts with GMCL1, but not its paralog GMCL2, and we map their interaction domains. CRL3 functions as a ubiquitin ligase that targets 53BP1 for degradation during the M phase, thereby reducing p53 accumulation in daughter cells. Depletion of GMCL1 inhibits cell cycle progression upon release from prolonged mitotic arrest, a defect that is rescued by co-silencing 53BP1 or USP28. Moreover, GMCL1 depletion sensitizes cancer cells to paclitaxel in a p53-dependent manner. Together, our findings support a model in which dysregulated CRL3-mediated degradation of 53BP1 prevents proper MSP function, leading to p53 degradation and continued proliferation. Targeting GMCL1 may, therefore, represent one possible avenue for addressing paclitaxel resistance in cancer cells with functional p53.

> **中文摘要：**
> 有丝分裂监测途径负责监测细胞周期中有丝分裂（M期）的持续时间。由纺锤体附着缺陷或微管靶向药物引起的M期延长，会触发由53BP1、USP28和p53组成的三元“有丝分裂秒表途径”复合物（MSP）的形成。该复合物可稳定p53，从而导致子代细胞发生细胞周期停滞或凋亡。在对紫杉醇（一种微管靶向剂）耐药的癌症中，细胞会绕过有丝分裂监测的激活，从而实现不受限制的增殖，但其潜在机制仍不清楚。在此，我们将GMCL1鉴定为MSP信号传导的关键负调节因子。我们证明53BP1与GMCL1发生物理相互作用，但与其旁系同源物GMCL2不发生相互作用，并绘制了它们的相互作用结构域。CRL3作为一种泛素连接酶，在M期靶向53BP1进行降解，从而减少子代细胞中p53的积累。耗竭GMCL1会抑制细胞从延长的有丝分裂停滞中释放后的细胞周期进展，而这一缺陷可以通过共同沉默53BP1或USP28来挽救。此外，GMCL1的耗竭能以p53依赖的方式使癌细胞对紫杉醇敏感。总之，我们的研究结果支持一个模型，即失调的CRL3介导的53BP1降解阻碍了正常的MSP功能，导致p53降解并持续增殖。因此，靶向GMCL1可能代表了解决具有功能性p53癌细胞中紫杉醇耐药性的一种潜在途径。

### 第二部分 AI 大师评价

该研究深入探讨了细胞有丝分裂监测途径（MSP）的分子调节机制，发现GMCL1通过作为CRL3泛素连接酶的底物适配器，在M期介导53BP1的降解，从而抑制p53的稳定性。研究揭示了癌细胞逃避有丝分裂监测并产生紫杉醇耐药的新机制，并通过细胞实验证明敲降GMCL1可有效恢复MSP功能并增强化疗敏感性。这一发现为针对野生型p53癌症开发克服紫杉醇耐药的新型靶向药物提供了坚实的生物学基础。

---

## 2. ENPP1调控的细胞外嘌呤代谢驱动胰腺炎介导的胰腺癌发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41553309)
**期刊：** Gastroenterology
**PMID：** 41553309
**DOI：** 10.1053/j.gastro.2025.09.032

### 第一部分 原文与翻译

**英文原标题：** ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer.

> **英文摘要：**
> BACKGROUND & AIMS: Patients with chronic pancreatitis (CP) have a higher risk of developing pancreatic ductal adenocarcinoma (PDAC). Although pancreatitis has been found to promote PDAC initiation and progression, its role in PDAC tumorigenesis remains poorly understood. METHODS: A multiomics analysis of the transcriptome, proteome, and metabolome was performed in human pancreatic samples from patients with CP and CP-related PDAC (CP-PDAC). The CP-PDAC model was constructed in Ptf1a; LSL-Kras mice and Ptf1a; LSL-Kras; ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1) mice. Single-cell sequencing analysis of pancreatic tissue samples from Ptf1a; LSL-Kras mice and Ptf1a; LSL-Kras; Enpp1 mice revealed the role of the immune microenvironment in the progression from pancreatitis to cancer. Pharmacologic ENPP1 inhibition was studied in the orthotopic transplantation model and CP-PDAC model mice. RESULTS: Multiomics analysis of samples from patients with CP and CP-PDAC revealed that ENPP1-regulated extracellular purine metabolism plays an important role in pancreatitis-cancer transformation. Mechanistically, inflammatory damage to pancreatic acinar cells leads to the release of purine nucleotide metabolites, which are degraded by ENPP1-CD73 on the surface of pancreatic stellate cells into adenosine. This process activates pancreatic stellate cells and promotes fibrosis. Activated pancreatic stellate cells then release CXCL17, which recruits myeloid-derived suppressor cells and regulatory T cells in the microenvironment, resulting in immunosuppressive effects. Finally, ENPP1 was confirmed to be an effective target for immunotherapy in PDAC and early intervention in pancreatitis-cancer transformation. CONCLUSIONS: The study results identified ENPP1 as a contributor to pancreatitis-mediated pancreatic cancer and a potential therapeutic target for pancreatic carcinogenesis.

> **中文摘要：**
> 背景与目的：慢性胰腺炎（CP）患者发生胰腺导管腺癌（PDAC）的风险较高。尽管研究发现胰腺炎能促进PDAC的起始和进展，但其在PDAC肿瘤发生中的作用仍不甚明了。方法：对来自CP患者和CP相关PDAC（CP-PDAC）患者的人类胰腺样本进行了转录组、蛋白质组和代谢组的多组学分析。在Ptf1a; LSL-Kras小鼠和Ptf1a; LSL-Kras; 胞外核苷酸焦磷酸酶/磷酸二酯酶1（Enpp1）小鼠中构建了CP-PDAC模型。对Ptf1a; LSL-Kras小鼠和Ptf1a; LSL-Kras; Enpp1小鼠胰腺组织样本的单细胞测序分析揭示了免疫微环境在从胰腺炎向癌症进展过程中的作用。在原位移植模型和CP-PDAC模型小鼠中研究了药物抑制ENPP1的效果。结果：对CP和CP-PDAC患者样本的多组学分析表明，ENPP1调控的细胞外嘌呤代谢在胰腺炎-癌症转化中发挥重要作用。从机制上讲，胰腺腺泡细胞的炎症损伤导致嘌呤核苷酸代谢物的释放，这些代谢物被胰腺星状细胞表面的ENPP1-CD73降解为腺苷。这一过程激活了胰腺星状细胞并促进了纤维化。激活的胰腺星状细胞随后释放CXCL17，在微环境中募集髓源性抑制细胞和调节性T细胞，从而产生免疫抑制效应。最后，证实了ENPP1是PDAC免疫治疗和胰腺炎-癌症转化早期干预的有效靶点。结论：研究结果确定了ENPP1是胰腺炎介导的胰腺癌的促成因素，也是胰腺癌发生的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究通过整合临床多组学分析与基因工程小鼠模型，深入揭示了ENPP1在慢性胰腺炎向胰腺癌演变过程中的代谢驱动机制。研究发现炎症诱导的ENPP1-CD73轴能通过产生腺苷激活胰腺星状细胞并募集免疫抑制细胞，构建了利于肿瘤发生的免疫微环境。其创新之处在于界定了胞外嘌呤代谢在炎症促癌转化中的核心地位，并证实了ENPP1作为早期干预及免疫治疗靶点的巨大潜力。

---

## 3. 基线检查中发现的锯齿状息肉与第二次随访结肠镜检查中发现的高级病变之间的关联：来自新罕布什尔州结肠镜登记库的数据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41553308)
**期刊：** Gastroenterology
**PMID：** 41553308
**DOI：** 10.1053/j.gastro.2025.11.023

### 第一部分 原文与翻译

**英文原标题：** Association Between Serrated Polyps on Index Examination and Advanced Findings Detected on the Second Surveillance Colonoscopy: Data From the New Hampshire Colonoscopy Registry.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究利用新罕布什尔州结肠镜登记库（NHCR）的大样本数据，旨在评估基线结肠镜检查中检出的锯齿状息肉与后续第二次随访检查中出现高级病变（如进展期腺瘤或结直肠癌）的长远关联。该研究聚焦于结直肠癌预防领域中日益受到关注的锯齿状通路，探讨了这类病变在长期监测中的临床预后意义。尽管目前PubMed未提供详细摘要，但其发表于《Gastroenterology》这一消化领域顶级期刊，反映了该研究在优化结肠镜随访策略及精准评估高风险人群方面具有重要的学术价值。

---

## 4. NSCLC中非V600 BRAF变异的生物学特性及临床管理

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41553307)
**期刊：** Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
**PMID：** 41553307
**DOI：** 10.1016/j.jtho.2025.12.001

### 第一部分 原文与翻译

**英文原标题：** Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.

> **英文摘要：**
> BRAF mutations are detected in approximately 3% to 8% of patients with NSCLC. In contrast to melanoma, in which most BRAF mutations occur at the V600 codon, only approximately 35% of BRAF-mutant NSCLC tumors harbor V600 mutations. Among the remaining cases, 60% to 70% present non-V600 mutations, primarily in exons 11 and 15. BRAF mutations are classified into three classes according to their kinase activity and their dependence on RAS activation. Compared with class I (V600), patients with class II and class III mutations are associated with poorer clinical outcomes partly due to the lack of effective targeted therapeutic strategies. Indeed, although dual BRAF and MEK inhibition has demonstrated clinical benefit in BRAF V600-mutant NSCLC, there is currently no consensus on treatment strategies for patients with class II and class III mutations. Beyond point mutations, other BRAF alterations (e.g., gene fusions, deletions, and amplifications) have been identified in treatment-naive tumors and in the context of acquired resistance to targeted therapies in other oncogene-driven NSCLC subtypes. However, the biology and clinical implications of these alterations remain poorly characterized. In this review, we provide a comprehensive overview on the biology, epidemiology, and therapeutic strategies of class II/III BRAF mutations, fusions, deletions, and amplifications in NSCLC. We highlight current challenges in the clinical management of BRAF-mutant NSCLC, emerging inhibitors, and combinatorial therapeutic strategies developed to treat non-V600E BRAF-driven cancers. Finally, we briefly discuss BRAF alterations in the context of resistance to targeted therapies in other oncogene-driven NSCLC.

> **中文摘要：**
> BRAF突变在约3%至8%的非小细胞肺癌（NSCLC）患者中被检出。与大多数BRAF突变发生于V600密码子的黑色素瘤不同，仅有约35%的BRAF突变型NSCLC肿瘤携带V600突变。在剩余病例中，60%至70%表现为非V600突变，主要位于外显子11和15。根据激酶活性及对RAS激活的依赖性，BRAF突变被分为三类。与I类（V600）相比，II类和III类突变患者的临床预后较差，部分归因于缺乏有效的靶向治疗策略。事实上，尽管BRAF和MEK双重抑制已在BRAF V600突变型NSCLC中显示出临床获益，但目前对于II类和III类突变患者的治疗策略尚未达成共识。除点突变外，在初治肿瘤以及其他癌基因驱动的NSCLC亚型对靶向治疗产生获得性耐药的情况下，也发现了其他BRAF变异（如基因融合、缺失和扩增）。然而，这些变异的生物学特性和临床意义仍未得到充分表征。在本综述中，我们全面概述了NSCLC中II/III类BRAF突变、融合、缺失和扩增的生物学、流行病学及治疗策略。我们重点介绍了BRAF突变型NSCLC临床管理中的当前挑战、新兴抑制剂以及为治疗非V600E BRAF驱动的癌症而开发的联合治疗策略。最后，我们简要讨论了在其他癌基因驱动的NSCLC中，作为靶向治疗耐药机制的BRAF变异。

### 第二部分 AI 大师评价

本综述全面总结了NSCLC中非V600 BRAF变异（包括II/III类突变、融合及扩增等）的分子生物学特征、流行病学现状及临床管理策略。文章强调了非V600变异相较于典型V600突变在激酶活性及治疗响应上的显著异质性，并指出了此类患者在缺乏标准化靶向方案下的预后困境。通过系统梳理新兴抑制剂和联合用药方案，该综述为解决非V600 BRAF驱动肿瘤的临床挑战提供了关键的理论依据与前瞻性的治疗视野。

---

## 5. 染色体外DNA与癌症：功能、形成及其临床意义

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549303)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41549303
**DOI：** 10.1186/s13046-026-03639-0

### 第一部分 原文与翻译

**英文原标题：** Extrachromosomal DNA and cancer: function, formation, and clinical implications.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献聚焦于肿瘤基因组学的前沿领域，系统探讨了染色体外DNA（ecDNA）在癌症发生发展中的核心作用。文章深入阐述了ecDNA的形成机制、其对癌基因扩增的影响，以及在驱动肿瘤异质性和耐药性方面的临床意义。尽管目前缺乏详细摘要，但其标题揭示了该综述涵盖了从基础生物学功能到临床转化应用的完整逻辑框架，对理解癌症进化的非经典遗传模式具有重要价值。

---

## 6. TriCON：一种用于胰腺癌治疗的碳基三模态纳米平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549285)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41549285
**DOI：** 10.1002/advs.202512978

### 第一部分 原文与翻译

**英文原标题：** TriCON: A Carbon-Based Triple-Modal Nanoplatform for Pancreatic Cancer Therapy.

> **英文摘要：**
> Pancreatic cancer, recognized for its high malignancy and tumor immunosuppressive microenvironment, has been refractory to conventional therapeutic modalities, necessitating the exploration of novel treatment strategies. Among these, reprogramming of the tumor immunosuppressive microenvironment is a promising strategy to enhance the efficacy of tumor immunotherapy. The CRISPR/Cas9 system-based gene editing further offers a viable approach for precise regulation of endogenous gene expression associated with tumor immunosuppression. Current delivery vectors face a trilemma between biosafety profiles, expansion capacity, and targeting accuracy. To this end, we developed a triple-modality therapeutic platform, termed TriCON (Triple Convergent Oncology Nanotherapy), characterized by three core mechanistic attributes: spatiotemporal convergence, stimuli-responsive controllability, and tumor-microenvironment modulatory conductivity. This orchestrated combination of rationally designed gene editing (targeting poliovirus receptor), nano-encapsulated doxorubicin (DOX) chemotherapy, and checkpoint blockade immunotherapy demonstrated enhanced synergistic antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models, achieving tumor regression through enhanced chemotherapy, immunogenic cell death induction, and natural killer (NK) cells activation. The platform achieved superior in vivo gene editing (14.2% PVR editing efficiency) via optimized endosomal escape and CRISPR system release. This triaxial approach establishes a programmable nanotherapeutic paradigm that synergizes gene editing precision with chemo-immunotherapy, offering a novel framework for PDAC treatment.

> **中文摘要：**
> 胰腺癌因其高恶性程度和肿瘤免疫抑制微环境而臭名昭著，传统治疗方案往往难以奏效，因此迫切需要探索新型治疗策略。其中，重塑肿瘤免疫抑制微环境是增强肿瘤免疫治疗效果的一种极具前景的策略。基于 CRISPR/Cas9 系统的基因编辑为精确调节与肿瘤免疫抑制相关的内源性基因表达提供了一种可行的方法。目前的递送载体在生物安全性、负载能力和靶向准确性之间面临着“三难困境”。为此，我们开发了一种名为 TriCON（三项汇聚肿瘤纳米疗法）的三模态治疗平台，其特点是具有三个核心机制属性：时空汇聚性、刺激响应可控性和肿瘤微环境调节传导性。这种精心设计的组合方案——包括针对脊髓灰质炎病毒受体（PVR）的基因编辑、纳米包裹的阿霉素（DOX）化疗以及免疫检查点阻断疗法——在胰腺导管腺癌（PDAC）模型中表现出增强的协同抗肿瘤活性。该平台通过增强化疗效果、诱导免疫原性细胞死亡以及激活自然杀伤（NK）细胞，实现了肿瘤退缩。通过优化内体逃逸和 CRISPR 系统释放，该平台实现了优异的体内基因编辑效果（PVR 编辑效率达 14.2%）。这种三轴方法建立了一种可编程的纳米治疗范式，将基因编辑的精准性与化疗-免疫治疗相结合，为 PDAC 治疗提供了一个全新的框架。

### 第二部分 AI 大师评价

本研究创新性地构建了名为 TriCON 的碳基纳米平台，旨在克服胰腺导管腺癌（PDAC）对常规疗法的耐药性及免疫抑制屏障。通过将针对 PVR 基因的 CRISPR/Cas9 精准编辑、DOX 化学治疗与免疫检查点阻断有机整合，该研究实现了时空可控的多模态协同，并在体内达到了 14.2% 的高效基因编辑水平。研究亮点在于成功诱导了肿瘤免疫原性细胞死亡并激活了 NK 细胞介导的抗肿瘤免疫，为解决纳米载体递送瓶颈及开发可编程胰腺癌联合疗法提供了重要范例。

---

## 7. METTL3 介导的 CACNA1E m6A 修饰通过增强 WNT7B 介导的钙信号传导促进骨肉瘤进展及化疗耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549277)
**期刊：** Molecular cancer
**PMID：** 41549277
**DOI：** 10.1186/s12943-025-02553-x

### 第一部分 原文与翻译

**英文原标题：** METTL3-mediated mA modification of CACNA1E promotes osteosarcoma progression and chemoresistance by enhancing WNT7B-mediated Ca signaling.

> **英文摘要：**
> BACKGROUND: Osteosarcoma (OS) is the most prevalent primary cancer of the bone. Metastasis and chemoresistance are the major obstacles to the improvement of OS prognosis, in which N-methyladenosine (mA) modification plays an important role, but the exact molecular mechanisms are still unclear.
> 
> METHODS: MeRIP-seq and RNA-seq were conducted on OS and paired adjacent normal tissue samples, which determined CACNA1E as a key mA-modified molecule. In vitro and in vivo models were established to evaluate the function of CACNA1E on OS growth, metastasis, and methotrexate (MTX) resistance, and to explore the upstream regulators and downstream effectors of CACNA1E.
> 
> RESULTS: CACNA1E exhibited notable mA hypermethylation and upregulated expression in OS than adjacent normal tissues. CACNA1E knockdown effectively hindered OS growth, lung metastasis, and MTX resistance. METTL3, an mA "writer" boosted the mRNA stability of CACNA1E through mA modification, and this process was recognized and enhanced by IGF2BP2, an mA "reader". WNT7B was identified as a downstream molecule of CACNA1E. CACNA1E facilitated OS progression and MTX resistance by enhancing the non-canonical Wnt/Ca signaling through transcriptionally activating WNT7B. Furthermore, a novel combination treatment of targeted inhibition of CACNA1E with MTX had a synergistic effect on suppressing OS progression.
> 
> CONCLUSIONS: Collectively, our findings uncover that METTL3-mediated mA modification of CACNA1E contributes to OS progression and chemoresistance through enhancing WNT7B-mediated non-canonical Wnt/Ca signaling. Targeted inhibition of CACNA1E in combination with MTX may be a promising alternative therapeutic strategy for patients with MTX-resistant OS.

> **中文摘要：**
> 背景：骨肉瘤（OS）是最常见的原发性骨癌。转移和化疗耐药是改善骨肉瘤预后的主要障碍，其中 N6-甲基腺苷（m6A）修饰在其中发挥着重要作用，但确切的分子机制仍不清楚。
> 方法：对骨肉瘤及其配对的邻近正常组织样本进行 MeRIP-seq 和 RNA-seq 测序，确定 CACNA1E 为关键的 m6A 修饰分子。建立体外和体内模型以评估 CACNA1E 对骨肉瘤生长、转移和甲氨蝶呤（MTX）耐药的功能，并探索 CACNA1E 的上游调节因子和下游效应因子。
> 结果：与邻近正常组织相比，CACNA1E 在骨肉瘤中表现出显著的 m6A 高甲基化和表达上调。敲低 CACNA1E 可有效阻碍骨肉瘤生长、肺转移和甲氨蝶呤耐药。m6A“写入器”METTL3 通过 m6A 修饰增强了 CACNA1E 的 mRNA 稳定性，这一过程被 m6A“阅读器”IGF2BP2 识别并增强。WNT7B 被鉴定为 CACNA1E 的下游分子。CACNA1E 通过转录激活 WNT7B 增强非经典 Wnt/钙信号传导，从而促进骨肉瘤进展和甲氨蝶呤耐药。此外，靶向抑制 CACNA1E 联合甲氨蝶呤的一种新型联合疗法在抑制骨肉瘤进展方面具有协同效应。
> 结论：总的来说，我们的研究结果揭示了 METTL3 介导的 CACNA1E m6A 修饰通过增强 WNT7B 介导的非经典 Wnt/钙信号传导，促进了骨肉瘤的进展和化疗耐药。靶向抑制 CACNA1E 联合甲氨蝶呤可能是甲氨蝶呤耐药骨肉瘤患者的一种有前景的替代治疗策略。

### 第二部分 AI 大师评价

本研究深入探讨了 m6A 表观遗传修饰在骨肉瘤进展中的调控机制，首次揭示了 METTL3/IGF2BP2/CACNA1E 信号轴在驱动肿瘤转移和甲氨蝶呤耐药中的关键作用。通过多组学技术与体内外实验，研究明确了 CACNA1E 作为 m6A 靶点通过激活非经典 Wnt/Ca2+ 通路促进病理进程的具体分子路径。其创新性在于发现了钙通道蛋白受 m6A 修饰调控的新模式，并提出了靶向 CACNA1E 联合化疗的协同治疗策略，为克服骨肉瘤耐药提供了坚实的理论依据和潜在临床靶点。

---

## 8. 全类聚乙二醇（PEG）嵌段共聚物自组装成用于药物递送的隐身纳米载体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549226)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41549226
**DOI：** 10.1002/advs.202517048

### 第一部分 原文与翻译

**英文原标题：** All-PEG-Like Block Copolymers Self-Assemble into Stealth Nanocarriers for Drug Delivery.

> **英文摘要：**
> Poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) is a stealth polymer that does not exhibit polyethylene glycol (PEG) antigenicity. Herein, we engineered self-assembling nanoparticles composed entirely of POEGMA by designing AB diblock copolymers with varying oligo(ethylene glycol) (EG) side chains. We found that a one-unit difference between di- and tri-ethylene glycol side chains is sufficient to induce amphiphilicity and enables temperature-triggered self-assembly above room temperature when the block length ratio is at least 0.25. To broaden the temperature stability window, we increased amphiphilicity by incorporating mono-ethylene glycol into the hydrophobic block via random copolymerization, yielding nanoparticles stable between 20°C-40°C. These POEGMA nanoparticles effectively encapsulate diverse hydrophobic drugs with high loading efficiency. Notably, POEGMA-encapsulated doxorubicin retained the drug's in vitro activity and exhibited enhanced in vivo efficacy compared to free doxorubicin due to improved pharmacokinetics. Furthermore, these nanoparticles demonstrated stealth behavior by evading recognition by anti-PEG antibodies. This study introduces a versatile, fully POEGMA-based platform for stealth drug delivery with tunable thermal responsiveness and high therapeutic potential.

> **中文摘要：**
> 聚（低聚乙二醇甲醚甲基丙烯酸酯）（POEGMA）是一种不表现出聚乙二醇（PEG）抗原性的隐身聚合物。在此，我们通过设计具有不同低聚乙二醇（EG）侧链的AB型双嵌段共聚物，构建了完全由POEGMA组成的自组装纳米颗粒。我们发现，二甘醇和三甘醇侧链之间仅一个单元的差异就足以诱导两亲性，并在嵌段长度比例至少为0.25时，实现在室温以上的温度触发自组装。为了拓宽温度稳定窗口，我们通过随机共聚将单甘醇引入疏水嵌段以增强两亲性，从而获得了在20°C至40°C之间稳定的纳米颗粒。这些POEGMA纳米颗粒能够以高负载效率有效包裹多种疏水性药物。值得注意的是，由于药代动力学的改善，POEGMA包裹的多柔比星保留了药物的体外活性，并表现出优于游离多柔比星的体内疗效。此外，这些纳米颗粒通过逃避抗PEG抗体的识别展示了隐身行为。本研究介绍了一个通用的、完全基于POEGMA的隐身药物递送平台，具有可调的热响应性和极高的治疗潜力。

### 第二部分 AI 大师评价

本研究创新性地构建了完全由POEGMA组成的新型双嵌段共聚物纳米平台，利用侧链长度的微小差异精细调控材料的两亲性与热响应自组装行为。该系统成功解决了传统PEG载体易产生的免疫原性问题，通过规避抗PEG抗体识别实现了卓越的隐身功能。实验证实该平台在提升疏水性药物药代动力学及体内疗效方面具有显著优势，为开发下一代高性能、非抗原性隐身纳米药物载体提供了重要的设计思路。

---

## 9. 用于肺癌NIR-II荧光/19F核磁共振/光声成像及光疗的氟化缺氧响应型氮杂氟硼荧

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549220)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41549220
**DOI：** 10.1002/advs.202521886

### 第一部分 原文与翻译

**英文原标题：** Fluorinated Hypoxia-Responsive Aza-BODIPY for NIR-II FL/F MR/PA Imaging and Phototherapy of Lung Cancer.

> **英文摘要：**
> Tumor hypoxia limits the efficacy of photodynamic therapy (PDT), necessitating photosensitizers with hypoxia-adaptive therapy and imaging. Here, we present a fluorinated N-oxide aza-BODIPY (OFBD) nanoemulsion (OFBD-NP) for hypoxia-responsive, multimodal imaging-guided phototherapy. OFBD generates robust singlet oxygen under normoxia for PDT, but is reduced by CYP450 enzymes in hypoxic cells to photothermal-potent FBD, enabling switchable PDT/PTT. Co-assembly with fluorinated oil enhances oxygen delivery, boosts F MRI sensitivity, and promotes J-aggregation, shifting fluorescence into the NIR-II window for deep-tissue imaging. The redox conversion also activates photoacoustic signals, enabling responsive tri-modal imaging (NIR-II FLI/F MRI/PAI). OFBD-NP shows potent cytotoxicity in vitro under both normoxic and hypoxic conditions via apoptosis. In vivo, it selectively accumulates in tumors, offers high-contrast imaging, and leads to complete tumor regression in subcutaneous A549 models after laser irradiation, without systemic toxicity. This work demonstrates a smart nanoplatform that integrates deep-tissue imaging and hypoxia-triggered therapeutic switching, addressing major limitations of conventional photosensitizers in cancer imaging and phototherapy.

> **中文摘要：**
> 肿瘤缺氧限制了光动力疗法（PDT）的疗效，因此需要具备缺氧自适应治疗和成像能力的光敏剂。在此，我们开发了一种氟化N-氧化物氮杂氟硼荧（OFBD）纳米乳液（OFBD-NP），用于缺氧响应的多模态成像引导光疗。OFBD在常氧条件下产生强效单线态氧用于PDT，但在缺氧细胞中会被CYP450酶还原为具有光热潜力的FBD，从而实现可切换的PDT/PTT。通过与氟化油共组装，该体系增强了氧气输送，提升了19F核磁共振成像（MRI）的灵敏度，并促进了J-聚集，使荧光红移至NIR-II窗口以进行深层组织成像。这种氧化还原转化还激活了光声信号，实现了响应式三模态成像（NIR-II FLI/19F MRI/PAI）。OFBD-NP在体外常氧和缺氧条件下均能通过凋亡表现出强大的细胞毒性。在体内，它能选择性地蓄积在肿瘤中，提供高对比度成像，并在激光照射后导致皮下A549肺癌模型中的肿瘤完全消退，且未观察到全身毒性。该研究展示了一个集深层组织成像与缺氧触发治疗切换于一体的智能纳米平台，解决了传统光敏剂在癌症成像和光疗中的主要局限性。

### 第二部分 AI 大师评价

该研究设计了一种创新的氟化氮杂氟硼荧纳米平台（OFBD-NP），核心亮点在于利用肿瘤微环境中的CYP450酶实现了从光动力（PDT）到光热（PTT）的智能治疗模式切换，有效克服了缺氧对传统PDT的限制。通过氟化油共组装策略，不仅显著增强了19F MRI和NIR-II荧光成像性能，还实现了对肿瘤区域的高灵敏三模态引导监测。实验结果显示其在肺癌模型中具有卓越的疗效和良好的生物安全性，为解决复杂肿瘤微环境下的精准诊疗提供了新思路。

---

## 10. AHCY-腺苷复合物重塑 mRNA 甲基化以增强脂肪酸生物合成和肿瘤发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549122)
**期刊：** Cell research
**PMID：** 41549122
**DOI：** 10.1038/s41422-025-01213-5

### 第一部分 原文与翻译

**英文原标题：** The AHCY-adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis.

> **英文摘要：**
> Methionine metabolism generates the substrate S-adenosylmethionine (SAM), which regulates epigenetic modifications crucial for various cellular processes, particularly tumorigenesis. However, whether methionine metabolism involves epigenetic mechanisms independent of SAM and what roles such mechanisms play in tumorigenesis remain unclear. We show here that the adenosylhomocysteinase (AHCY)-adenosine complex increases mRNA m6A levels in a non-global manner, promoting fatty acid synthesis and tumorigenesis. Adenosine increases mRNA m6A levels by binding to the methionine metabolism enzyme AHCY to form a complex, rather than depending on adenosine receptors. The AHCY-adenosine complex facilitates AHCY dimerization, with adenosine being crucial for dimer stability. AHCY dimers hinder the binding of fat mass and obesity-associated protein (FTO) at the Q86 site to RNA containing the VWDRACH motif, increasing m6A levels and upregulating lipogenesis genes, especially ACACA and SCD1, thus leading to reprogramming of lipid metabolism. Conversely, AHCY mutants that have lost dimerization or FTO-binding ability but retain hydrolase activity suppress lipogenesis and tumor growth without significantly affecting methionine catabolism mediated by AHCY. Loss of AHCY in mice and disruption of AHCY dimerization in tumor cells and patient-derived xenograft models restricted tumor growth. Our findings demonstrate a key SAM-independent link between methionine metabolism and mRNA m6A modification that affects demethylase substrate specificity. This novel link between the methionine cycle and lipid metabolism suggests new strategies for anticancer therapy.

> **中文摘要：**
> 蛋氨酸代谢产生底物 S-腺苷蛋氨酸 (SAM)，它调节对各种细胞过程（特别是肿瘤发生）至关重要的表观遗传修饰。然而，蛋氨酸代谢是否涉及独立于 SAM 的表观遗传机制，以及这些机制在肿瘤发生中起何种作用，目前尚不清楚。我们在此展示，腺苷同型半胱氨酸酶 (AHCY)-腺苷复合物以非全局方式增加 mRNA 的 m6A 水平，从而促进脂肪酸合成和肿瘤发生。腺苷通过与蛋氨酸代谢酶 AHCY 结合形成复合物，而不是依赖腺苷受体来增加 mRNA 的 m6A 水平。AHCY-腺苷复合物促进 AHCY 二聚化，其中腺苷对二聚体稳定性至关重要。AHCY 二聚体在 Q86 位点阻碍脂肪质量和肥胖相关蛋白 (FTO) 与含有 VWDRACH 基序的 RNA 结合，从而提高 m6A 水平并上调脂质合成基因（尤其是 ACACA 和 SCD1），进而导致脂质代谢重编程。相反，失去二聚化或 FTO 结合能力但保留水解酶活性的 AHCY 突变体可以抑制脂质合成和肿瘤生长，且不会显著影响由 AHCY 介导的蛋氨酸分解代谢。在小鼠中缺失 AHCY 以及在肿瘤细胞和患者来源的异种移植模型中破坏 AHCY 二聚化均限制了肿瘤生长。我们的研究结果证明了蛋氨酸代谢与 mRNA m6A 修饰之间一种关键的非 SAM 依赖性联系，这种联系影响了去甲基化酶的底物特异性。这种蛋氨酸循环与脂质代谢之间的新型联系为抗癌治疗提供了新策略。

### 第二部分 AI 大师评价

该研究揭示了蛋氨酸代谢通过非SAM依赖途径调节表观遗传的新机制，发现AHCY-腺苷复合物通过促进AHCY二聚化，竞争性阻碍去甲基化酶FTO对特定mRNA基序的识别。这一过程精准上调了脂质合成关键基因ACACA和SCD1，从而驱动代谢重编程及肿瘤进展。研究通过细胞、小鼠及PDX模型充分验证了阻断AHCY二聚化在抗肿瘤治疗中的潜力。其创新性在于打破了蛋氨酸代谢仅通过SAM底物影响甲基化的传统认知，为靶向“代谢-表观遗传”轴提供了重要科学依据。

---

## 11. 通过模拟果蝇组织特异性代谢揭示高糖饮食诱导的肌肉反应及通路水平代谢失调

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41549107)
**期刊：** Nature communications
**PMID：** 41549107
**DOI：** 10.1038/s41467-026-68395-3

### 第一部分 原文与翻译

**英文原标题：** Modeling tissue-specific Drosophila metabolism identifies high sugar diet-induced metabolic dysregulation in muscle at reaction and pathway levels.

> **英文摘要：**
> Individual tissues perform highly specialized metabolic functions to maintain whole-body metabolic homeostasis. Although Drosophila serves as a powerful model for studying human metabolic diseases, modeling tissue-specific metabolism has been limited in this organism. To address this gap, we reconstruct 32 tissue-specific genome-scale metabolic models (GEMs) by integrating a curated Drosophila metabolic network with pseudo-bulk single-nuclei transcriptomics data, revealing distinct metabolic network structures and subsystem coverage across tissues. We validate enriched pathways identified through tissue-specific GEMs, particularly in muscle and fat body, using metabolomics and pathway analysis. Moreover, to demonstrate the utility in disease modeling, we apply muscle-GEM to investigate high sugar diet (HSD)-induced metabolic dysregulation. Constraint-based semi-quantitative flux and sensitivity analyses identify altered NAD(H)-dependent reactions and distributed control of glycolytic flux, including GAPDH. This prediction is further validated through in vivo C-glucose isotope tracing study. Notably, decreased glycolytic flux, including GAPDH, is linked to increased redox modifications. Finally, our pathway-level flux analyses identify dysregulation in fructose metabolism. Together, this work establishes a quantitative framework for tissue-specific metabolic modeling in Drosophila, demonstrating its utility for identifying dysregulated reactions and pathways in muscle in response to HSD.

> **中文摘要：**
> 个体组织执行高度专业化的代谢功能以维持全身代谢稳态。尽管果蝇是研究人类代谢疾病的强大模型，但在该生物中模拟组织特异性代谢一直受到限制。为了弥补这一空白，我们通过整合精心策划的果蝇代谢网络与伪批量单核转录组学数据，重建了32个组织特异性全基因组规模代谢模型（GEMs），揭示了跨组织的不同代谢网络结构和子系统覆盖范围。我们利用代谢组学和通路分析验证了通过组织特异性GEMs确定的富集通路，特别是在肌肉和脂肪体中。此外，为了展示在疾病建模中的效用，我们应用肌肉GEM来研究高糖饮食（HSD）诱导的代谢失调。基于约束的半定量通量和敏感性分析确定了改变的NAD(H)依赖性反应和糖酵解通量的分布式控制，包括GAPDH。这一预测通过体内13C-葡萄糖同位素示踪研究得到了进一步验证。值得注意的是，包括GAPDH在内的糖酵解通量降低与氧化还原修饰的增加有关。最后，我们的通路级通量分析确定了果糖代谢的失调。总之，这项工作建立了一个果蝇组织特异性代谢建模的定量框架，展示了其在识别肌肉对高糖饮食响应中失调的反应和通路方面的效用。

### 第二部分 AI 大师评价

该研究通过整合单核转录组学数据，成功构建了首个涵盖果蝇32个组织的基因组规模代谢模型（GEMs）框架，有效解决了果蝇模型在组织特异性代谢建模方面的局限。研究精准识别了高糖饮食诱导下肌肉组织中GAPDH活性下降及果糖代谢失调等关键特征，并结合体内同位素示踪实验验证了预测结果。该工作不仅展示了系统生物学在解析复杂代谢病理中的强大功能，也为研究人类营养代谢疾病提供了高精度的定量模拟平台。

---

速递结束，祝您工作愉快！